Early diabetes treatment does not prevent sympathetic dysinnervation in the streptozotocin diabetic rat heart

Journal of Nuclear Cardiology

Volumn 21, Issue 4, 2014, Pages 829-841

  Thackeray, James T ^a,b,c   Dekemp, Robert A ^a   Beanlands, Rob S ^a,b   DaSilva, Jean N ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Metformin; norepinephrine; norepinephrine reuptake transporter; rosiglitazone; small animal echocardiography; small animal positron emission tomography

Indexed keywords

3 HYDROXYEPHEDRINE; GLUCOSE; INSULIN; METFORMIN; NORADRENALIN; ROSIGLITAZONE; STREPTOZOCIN; 3-HYDROXYEPHEDRINE; EPHEDRINE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORTER 4; SLC2A4 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DECELERATION; DIABETES MELLITUS; DIABETOGENESIS; DOPPLER ECHOCARDIOGRAPHY; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; HEART FUNCTION; IMMUNOBLOTTING; INSULIN TREATMENT; LIPID DIET; MALE; MITRAL VALVE; NEUROLOGIC DISEASE; NEURONAL DYSFUNCTION; NONHUMAN; NORADRENALIN BLOOD LEVEL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; SYMPATHETIC DYSINNERVATION; SYMPATHETIC INNERVATION; TREATMENT DURATION; ADRENERGIC SYSTEM; ANALOGS AND DERIVATIVES; ANALYSIS; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIAGNOSTIC USE; EARLY INTERVENTION; ECHOCARDIOGRAPHY; PATHOPHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; EARLY MEDICAL INTERVENTION; ECHOCARDIOGRAPHY; EPHEDRINE; GLUCOSE TRANSPORTER TYPE 4; MALE; NOREPINEPHRINE; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; SYMPATHETIC NERVOUS SYSTEM;

EID: 84905096535     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-014-9900-x     Document Type: Article

References (44)

1. Flaa A, Aksnes TA, Kjeldsen SE, Eide I, Rostrup M. Increased sympathetic reactivity may predict insulin resistance: An 18-year follow-up study. Metabolism 2008;57:1422-7.
2. Rosengard-Barlund M, Bernardi L, Fagerudd J, Mantysaari M, Af Bjorkesten CG, Lindholm H, et al. Early autonomic dysfunction in type 1 diabetes:Areversible disorder? Diabetologia 2009;52:1164-72.
3. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: The Atherosclerosis Risk in Communities study, 1987-1998. Circulation 2003;107:2190-5. (Pubitemid 36547211)
4. Sacre JW, Franjic B, Jellis CL, Jenkins C, Coombes JS, Marwick TH. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging 2010;3:1207-15.
5. Thackeray JT, Radziuk J, Harper ME, Suuronen EJ, Ascah KJ, Beanlands RS, et al. Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance with hyperglycemia. Cardiovasc Diabetol 2011;10:75.
6. 11C-meta-hydroxyephedrine retention in heart, lung, pancreas, and brown adipose tissue. J Nucl Med 2007;48:1733-40.
7. 11C-mHED and PET: From man to mouse? J Nucl Med 2010;51:1269-76.
8. Tipre DN, Fox JJ, Holt DP, Green G, Yu J, Pomper M, et al. In vivo PET imaging of cardiac presynaptic sympathoneuronal mechanisms in the rat. J Nucl Med 2008;49:1189-95. (Pubitemid 351948030)
9. 11C-meta- hydroxyephedrine measurements in rats by small animal positron emission tomography. Nucl Med Biol 2013;40:676-81.
10. Schmid H, Forman LA, Cao X, Sherman PS, Stevens MJ. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: Implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999;48:603-8. (Pubitemid 29106876)
11. Thackeray JT, deKemp RA, Beanlands RS, DaSilva JN. Insulin restores myocardial presynaptic sympathetic nervous integrity in insulin resistant diabetic rats. J Nucl Cardiol 2013;20:845-56.
12. Kiyono Y, Iida Y, Kawashima H, Ogawa M, Tamaki N, Nishimura H, et al. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging 2002;29:999-1005.
13. Kiyono Y, Iida Y, Kawashima H, Tamaki N, Nishimura H, Saji H. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: Implications for heterogeneous cardiac accumulation of MIBG in diabetes. Eur J Nucl Med 2001;28:894-9. (Pubitemid 32662552)
14. Marsh SA, Powell PC, Agarwal A, Dell'Italia LJ, Chatham JC. Cardiovascular dysfunction in Zucker obese and Zucker diabetic fatty rats: Role of hydronephrosis. Am J Physiol Heart Circ Physiol 2007;293:H292-8. (Pubitemid 47105084)
15. Thackeray JT, Parsa-Nezhad M, Kenk M, Thorn SL, Kolajova M, Beanlands RS, et al. Reduced CGP12177 binding to cardiac beta-adrenoceptors in hyperglycemic high-fat-diet-fed, streptozotocin-induced diabetic rats. Nucl Med Biol 2011;38:1059-66.
16. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 2007;76:280-91. (Pubitemid 350214455)
17. Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM. The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes 2001;50:455-61. (Pubitemid 32127304)
18. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, et al. A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism 2000;49:1390-4.
19. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009;104:403-11.
20. Verma S, McNeill JH. Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am J Physiol 1994;266:H714-9. (Pubitemid 24104818)
21. Choi SH, Zhao ZS, Lee YJ, Kim SK, Kim DJ, Ahn CW, et al. The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. Diabetes Metab Res Rev 2007;23:411-8. (Pubitemid 47091246)
22. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 2002;51:1110-7. (Pubitemid 34438357)
23. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005;54:554-62.
24. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
25. Arikawa E, Ma RC, Isshiki K, Luptak I, He Z, Yasuda Y, et al. Effects of insulin replacements, inhibitors of angiotensin, and PKCbeta's actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes 2007;56:1410-20. (Pubitemid 46715615)
26. Shoghi KI, Finck BN, Schechtman KB, Sharp T, Herrero P, Gropler RJ, et al. In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: Differential efficacy of metformin and rosiglitazone monotherapy. Circ Cardiovasc Imaging 2009;2:373-81.
27. Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, et al. Synthesis and preliminary evaluation of carbon-11-meta- hydroxyephedrine: A false transmitter agent for heart neuronal imaging. J Nucl Med 1990;31:1328-34. (Pubitemid 20245929)
28. Klein R, Beanlands RS, deKemp RA. Quantification of myocardial blood flow and flow reserve: Technical aspects. J Nucl Cardiol 2010;17:555-70.
29. Ding SY, Shen ZF, Chen YT, Sun SJ, Liu Q, Xie MZ. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacol Sin 2005;26:575-80. (Pubitemid 40676168)
30. Zhang F, Ye C, Li G, Ding W, Zhou W, Zhu H, et al. The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp Anim 2003;52:401-7. (Pubitemid 41349948)
31. Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, et al. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 2005;289:E328-36. (Pubitemid 41076636)
32. 11C-meta-hydroxyephedrine retention on norepinephrine transporter density. J Nucl Med 2006;47:1490-6.
33. Kusmic C, Morbelli S, Marini C, Matteucci M, Cappellini C, Pomposelli E, et al. Whole-body evaluation of MIBG tissue extraction in a mouse model of long-lasting type II diabetes and its relationship with norepinephrine transport protein concentration. J Nucl Med 2008;49:1701-6.
34. Di Carli MF, Tobes MC, Mangner T, Levine AB, Muzik O, Chakroborty P, et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med 1997;336:1208-15. (Pubitemid 27183650)
35. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: A randomized controlled trial. J Am Med Assoc 2009;301:1547-55.
36. Rizk N, Dunbar JC. Insulin-mediated increase in sympathetic nerve activity is attenuated by C-peptide in diabetic rats. Exp Biol Med (Maywood) 2004;229:80-4. (Pubitemid 38101682)
37. Stevens MJ, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: An assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism 1999;48:92-101. (Pubitemid 29035567)
38. Fricke E, Eckert S, Dongas A, Fricke H, Preuss R, Lindner O, et al. Myocardial sympathetic innervation in patients with symptomatic coronary artery disease: Follow-up after 1 year with neurostimulation. J Nucl Med 2008;49:1458-64.
39. Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD, et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 2009;297:H2096-108.
40. Raimondi L, De Paoli P, Mannucci E, Lonardo G, Sartiani L, Banchelli G, et al. Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes 2004;53:1927-33. (Pubitemid 38857056)
41. Li YJ, Wang PH, Chen C, Zou MH, Wang DW. Improvement of mechanical heart function by trimetazidine in db/db mice. Acta Pharmacol Sin 2010;31:560-9.
42. Manrique C, DeMarco VG, Aroor AR, Mugerfeld I, Garro M, Habibi J, et al. Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology 2013;154:3632-42.
43. Takashio S, Yamamuro M, Izumiya Y, Sugiyama S, Kojima S, Yamamoto E, et al. Coronary microvascular dysfunction and diastolic load correlate with cardiac troponin T release measured by a highly sensitive assay in patients with nonischemic heart failure. J Am Coll Cardiol 2013;62:632-40.
44. Gerson MC, Caldwell JH, Ananthasubramaniam K, Clements IP, Henzlova MJ, Amanullah A, et al. Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circ Cardiovasc Imaging 2011;4:87-93.